Physician
Almouie Pediatrics
Almouie Pediatrics was paid $23.01M by Medicaid between Jan 2018 and Nov 2022, across 116 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 17% of everything it billed.
33Billing provider infoALMOUIE PEDIATRICS
CORPUS CHRISTI, TX 78410
CORPUS CHRISTI, TX 78410
33aNPI1881742575assigned 01/08/2007
33bProvider typePediatrics Physician
28Total paid$23.01M
24GClaims1,223,715
24DCodes billed116
24AFirst – last monthJan 2018 – Nov 2022
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#8 of 1,136
Median peer was paid$329K
This provider vs. median70×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,347 | $128K | |
| 2019 | 3,751 | $104K | |
| 2020 | 135,780 | $2.41M | |
| 2021 | 589,318 | $11.25M | |
| 2022 | 490,519 | $9.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 161,523 | 147,094 | $3.91M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 101,966 | 94,708 | $3.24M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 9.2% | 29,158 | 28,541 | $2.12M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 9.1% | 53,703 | 51,350 | $2.10M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 7.7% | 25,862 | 24,710 | $1.77M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.5% | 23,054 | 22,436 | $1.72M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.0% | 14,652 | 14,195 | $1.16M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.9% | 148,592 | 57,793 | $1.14M |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.7% | 14,756 | 14,157 | $619K |
| 99381 | 1.9% | 6,453 | 6,168 | $439K | |
| 99429 | 1.9% | 22,643 | 21,810 | $426K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 5,238 | 5,076 | $392K |
104 more codes
| 99383 | 1.7% | 4,725 | $387K | |
| 99000 | 1.6% | 38,852 | $357K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.3% | 30,523 | $309K |
| 99382 | 1.3% | 3,575 | $290K | |
| 90461 | 1.1% | 46,361 | $255K | |
| 99384 | <1% | 2,504 | $219K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 27,022 | $214K |
| 92552 | <1% | 28,965 | $189K | |
| 87634 | <1% | 8,201 | $176K | |
| 99050 | <1% | 2,314 | $170K | |
| Q3014 | Telehealth originating site facility fee | <1% | 8,659 | $166K |
| 87400 | <1% | 21,488 | $158K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,616 | $145K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,161 | $140K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,617 | $120K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,094 | $70K |
| 87420 | <1% | 7,121 | $69K | |
| 83655 | <1% | 6,085 | $58K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 693 | $49K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 539 | $39K |
| 99001 | <1% | 14,663 | $35K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,486 | $33K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 109 | $33K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,712 | $31K |
| 87807 | <1% | 3,733 | $28K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,256 | $25K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 747 | $22K |
| 80050 | General health panel | <1% | 661 | $22K |
| 0001A | <1% | 500 | $18K | |
| 96160 | <1% | 9,831 | $16K | |
| 99051 | <1% | 1,078 | $15K | |
| 0002A | <1% | 335 | $13K | |
| 84439 | <1% | 1,780 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,839 | $10K |
| 80053 | Comprehensive metabolic panel | <1% | 2,791 | $10K |
| 81003 | <1% | 5,367 | $7K | |
| 80061 | Lipid panel | <1% | 598 | $5K |
| 97169 | <1% | 245 | $5K | |
| 87301 | <1% | 437 | $4K | |
| 90620 | <1% | 2,022 | $4K | |
| 90651 | <1% | 6,622 | $4K | |
| 96161 | <1% | 3,995 | $4K | |
| 94010 | <1% | 133 | $3K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 335 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 57 | $3K |
| 97803 | <1% | 471 | $3K | |
| 87581 | <1% | 101 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 255 | $3K |
| 0071A | <1% | 63 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 79 | $2K |
| 85027 | <1% | 875 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 294 | $2K |
| 90473 | <1% | 219 | $1K | |
| 90734 | <1% | 5,268 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 42 | $923.56 |
| 90686 | <1% | 13,924 | $849.94 | |
| 82951 | <1% | 103 | $840.58 | |
| 90670 | <1% | 20,689 | $815.98 | |
| 90716 | <1% | 10,306 | $743.86 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 56 | $700.46 |
| 86308 | <1% | 179 | $697.66 | |
| 0081A | <1% | 12 | $484.49 | |
| 87070 | <1% | 114 | $426.99 | |
| 90707 | <1% | 10,349 | $341.54 | |
| 36416 | <1% | 18,204 | $272.77 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 19 | $267.64 |
| 90696 | <1% | 4,278 | $249.95 | |
| 94375 | <1% | 14 | $241.71 | |
| 69210 | <1% | 18 | $210.65 | |
| 84030 | <1% | 2,860 | $200.60 | |
| 94760 | <1% | 309 | $154.44 | |
| 97802 | <1% | 31 | $151.30 | |
| 90715 | <1% | 3,443 | $139.16 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 127 | $137.69 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 142 | $101.38 |
| 99173 | <1% | 34,804 | $96.94 | |
| 90680 | <1% | 8,859 | $88.96 | |
| 90723 | <1% | 5,607 | $80.10 | |
| 90633 | <1% | 11,145 | $72.39 | |
| 90648 | <1% | 10,067 | $62.54 | |
| 90744 | <1% | 6,581 | $53.24 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 16 | $52.25 |
| 90672 | <1% | 222 | $25.33 | |
| 94761 | <1% | 15 | $14.60 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 33,530 | $11.53 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 16,581 | $9.15 |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 13,866 | $5.30 |
| G9716 | Bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason | <1% | 32,284 | $4.88 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 108 | $0.86 |
| 91300 | <1% | 722 | $0.10 | |
| 90681 | <1% | 3,731 | $0.05 | |
| 90697 | <1% | 196 | $0.05 | |
| 90732 | <1% | 12 | $0.04 | |
| 90621 | <1% | 108 | $0.02 | |
| 90710 | <1% | 134 | $0.01 | |
| 90700 | <1% | 5,249 | $0.01 | |
| 90698 | <1% | 9,716 | $0.01 | |
| 90713 | 0% | 274 | $0.00 | |
| 91308 | 0% | 55 | $0.00 | |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | 0% | 19 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 5,061 | $0.00 |
| 3008F | 0% | 349 | $0.00 | |
| 91307 | 0% | 467 | $0.00 | |
| 96127 | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALMOUIE, MUHAMAD (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Kidz Now Urgent Care PLLC | San Antonio, TX | $4.15M |
| Pediatricz Now Primary Care PLLC | Houston, TX | $375K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.